(CercleFinance.com) – Janssen announces positive results for JNJ-2113, a novel IL-23 receptor antagonist peptide, the first and only to be developed for the treatment of moderate to severe plaque psoriasis.
A greater proportion of patients who received JNJ-2113 achieved PASI 75 (primary endpoint) as well as PASI 90 and PASI 100 (75, 90, and 100 percent improvement in skin lesions as measured Psoriasis Area and Severity Index) versus placebo at Week 16.
The trial results for JNJ-2113 demonstrated a profile that supports its advancement into Phase 3 clinical development for moderate to severe plaque PsO in adult patients.
“Patients are looking for more flexible and convenient treatment options to manage the signs and symptoms of psoriasis, and these early positive results for JNJ-2113 are encouraging,” said Robert Bissonnette, Medical Director of Innovaderm. , Montreal, Canada.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
